Effectiveness and Safety of Anlotinib Combined with PD-1 Blockades in Patients with Previously Immunotherapy Treated Advanced Non-Small Cell Lung Cancer: A Retrospective Exploratory Study DOI Creative Commons

Xue-Jun Dou,

Run-Yang Ma,

De-Wang Ren

et al.

Lung Cancer Targets and Therapy, Journal Year: 2024, Volume and Issue: Volume 15, P. 29 - 40

Published: March 1, 2024

This study aimed to investigate the effectiveness and tolerability of anlotinib plus PD-1 blockades in patients with previously immunotherapy treated advanced non-small-cell lung cancer (NSCLC). A total 67 NSCLC who received clinical practice were screened retrospectively. All used this approved China consisted sintilimab, camrelizumab, tislelizumab pembrolizumab. Effectiveness safety assessed, all followed up regularly. Clinical significance between response status previous immune-related treatment regimens therapeutic outcomes was further explored. The best overall among suggested that a partial observed 16 patients, stable disease noted 41 progressive found 10 which yielded an objective rate 23.9% (95% CI: 14.3-35.9%) control 85.1% 74.3-92.6%). Prognostic indicated median progression-free survival (PFS) 6.1 months 2.37-9.83) (OS) 16.5 10.73-22.27). Exploratory analysis highlighted intolerant (17 patients) might have superior prognosis (median OS: 22.3 vs 12.5 months, P=0.024). Additionally, adverse reactions any grades during administration 62 (92.5%), 31 (46.3%) had ≥grade 3 reactions. Most common fatigue, hypertension, diarrhea hepatotoxicity. Anlotinib demonstrated promising tolerable NSCLC. Those benefit significantly from blockades. conclusion should be confirmed future studies.

Language: Английский

Heterogeneity of the tumor immune microenvironment and its clinical relevance DOI Creative Commons
Qingzhu Jia, Aoyun Wang,

Yixiao Yuan

et al.

Experimental Hematology and Oncology, Journal Year: 2022, Volume and Issue: 11(1)

Published: April 23, 2022

During the course of tumorigenesis and subsequent metastasis, malignant cells gradually diversify become more heterogeneous. Consequently, tumor mass might be infiltrated by diverse immune-related components, including cytokine/chemokine environment, cytotoxic activity, or immunosuppressive elements. This immunological heterogeneity is universally presented spatially varies temporally along with evolution therapeutic intervention across almost all solid tumors. The anti-tumor immunity shows a profound association progression disease responsiveness to treatment, particularly in realm immunotherapy. Therefore, an accurate understanding essential for development effective therapies. Facilitated multi-regional -omics sequencing, single cell longitudinal liquid biopsy approaches, recent studies have demonstrated potential investigate complexity tumors its clinical relevance Here, we aimed review mechanism underlying immune microenvironment. We also explored how assessments facilitate personalized

Language: Английский

Citations

130
Cancer Resistance to Immunotherapy: Comprehensive Insights with Future Perspectives DOI Creative Commons

Sawsan Sudqi Said,

Wisam Nabeel Ibrahim

Pharmaceutics, Journal Year: 2023, Volume and Issue: 15(4), P. 1143 - 1143

Published: April 4, 2023

Cancer immunotherapy is a type of treatment that harnesses the power immune systems patients to target cancer cells with better precision compared traditional chemotherapy. Several lines have been approved by US Food and Drug Administration (FDA) led remarkable success in solid tumors, such as melanoma small-cell lung cancer. These immunotherapies include checkpoint inhibitors, cytokines, vaccines, while chimeric antigen receptor (CAR) T-cell has shown responses hematological malignancies. Despite these breakthrough achievements, response variable among patients, only small percentage gained from this treatment, depending on histological tumor other host factors. develop mechanisms avoid interacting circumstances, which an adverse effect how effectively they react therapy. arise either due intrinsic factors within or microenvironment (TME). When scenario used therapeutic setting, term “resistance immunotherapy” applied; “primary resistance” denotes failure respond start, “secondary relapse following initial immunotherapy. Here, we provide thorough summary internal external underlying resistance Furthermore, variety are briefly discussed, along recent developments employed prevent relapses focus upcoming initiatives improve efficacy for patients.

Language: Английский

Citations

53
Navigating tumor angiogenesis: therapeutic perspectives and myeloid cell regulation mechanism DOI Creative Commons
Fan Yang,

Gloria Lee,

Yi Fan

et al.

Angiogenesis, Journal Year: 2024, Volume and Issue: 27(3), P. 333 - 349

Published: April 6, 2024

Abstract Sustained angiogenesis stands as a hallmark of cancer. The intricate vascular tumor microenvironment fuels cancer progression and metastasis, fosters therapy resistance, facilitates immune evasion. Therapeutic strategies targeting vasculature have emerged transformative for treatment, encompassing anti-angiogenesis, vessel normalization, endothelial reprogramming. Growing evidence suggests the dynamic regulation by infiltrating myeloid cells, such macrophages, myeloid-derived suppressor cells (MDSCs), neutrophils. Understanding these regulatory mechanisms is pivotal in paving way successful vasculature-targeted treatments. interventions aimed to disrupt cell-mediated may reshape overcome resistance radio/chemotherapy immunotherapy.

Language: Английский

Citations

21
Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer DOI Creative Commons
Shan Liu,

Xingda Zhang,

Wenzheng Wang

et al.

Molecular Cancer, Journal Year: 2024, Volume and Issue: 23(1)

Published: Nov. 21, 2024

Metabolic alterations, a hallmark of cancer, enable tumor cells to adapt their environment by modulating glucose, lipid, and amino acid metabolism, which fuels rapid growth contributes treatment resistance. In primary breast metabolic shifts such as the Warburg effect enhanced lipid synthesis are closely linked chemotherapy failure. Similarly, metastatic lesions often display distinct profiles that not only sustain but also confer resistance targeted therapies immunotherapies. The review emphasizes two major aspects: mechanisms driving in both how unique environments sites further complicate treatment. By targeting vulnerabilities at stages, new strategies could improve efficacy existing provide better outcomes for cancer patients.

Language: Английский

Citations

17
Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition DOI Creative Commons
Antonino Glaviano,

Hannah Lau,

Lukas M. Carter

et al.

Journal of Hematology & Oncology, Journal Year: 2025, Volume and Issue: 18(1)

Published: Jan. 13, 2025

The tumor microenvironment (TME) is integral to cancer progression, impacting metastasis and treatment response. It consists of diverse cell types, extracellular matrix components, signaling molecules that interact promote growth therapeutic resistance. Elucidating the intricate interactions between cells TME crucial in understanding progression challenges. A critical process induced by epithelial-mesenchymal transition (EMT), wherein epithelial acquire mesenchymal traits, which enhance their motility invasiveness progression. By targeting various components TME, novel investigational strategies aim disrupt TME's contribution EMT, thereby improving efficacy, addressing resistance, offering a nuanced approach therapy. This review scrutinizes key players emphasizing avenues therapeutically components. Moreover, article discusses implications for resistance mechanisms highlights current toward modulation along with potential caveats.

Language: Английский

Citations

16
Research progress on tumor hypoxia-associative nanomedicine DOI
Xiaoxue Xu, Siyi Chen,

Ningbo Yi

et al.

Journal of Controlled Release, Journal Year: 2022, Volume and Issue: 350, P. 829 - 840

Published: Sept. 13, 2022

Language: Английский

Citations

54
Application of bismuth sulfide based nanomaterials in cancer diagnosis and treatment DOI

Zhongwei Yang,

Longwei Wang, Jian Zhang

et al.

Nano Today, Journal Year: 2023, Volume and Issue: 49, P. 101799 - 101799

Published: March 18, 2023

Language: Английский

Citations

27
A metal-organic framework (MOF) built on surface-modified Cu nanoparticles eliminates tumors via multiple cascading synergistic therapeutic effects DOI
Guanghui An, Heming Zheng, Lianshan Guo

et al.

Journal of Colloid and Interface Science, Journal Year: 2024, Volume and Issue: 662, P. 298 - 312

Published: Feb. 9, 2024

Language: Английский

Citations

14
An immunosuppressive vascular niche drives macrophage polarization and immunotherapy resistance in glioblastoma DOI Creative Commons
Fan Yang, Md. Naushad Akhtar, Duo Zhang

et al.

Science Advances, Journal Year: 2024, Volume and Issue: 10(9)

Published: Feb. 28, 2024

Cancer immunity is subjected to spatiotemporal regulation by leukocyte interaction with neoplastic and stromal cells, contributing immune evasion immunotherapy resistance. Here, we identify a distinct mesenchymal-like population of endothelial cells (ECs) that form an immunosuppressive vascular niche in glioblastoma (GBM). We reveal spatially restricted, Twist1/SATB1-mediated sequential transcriptional activation mechanism, through which tumor ECs produce osteopontin promote macrophage (Mφ) phenotypes. Genetic or pharmacological ablation Twist1 reverses Mφ-mediated immunosuppression enhances T cell infiltration activation, leading reduced GBM growth extended mouse survival, sensitizing chimeric antigen receptor immunotherapy. Thus, these findings uncover restricted mechanism controlling suggest targeting may offer attractive opportunities for optimizing cancer

Language: Английский

Citations

13
Exosome miR-199a-5p modulated vascular remodeling and inflammatory infiltration of Takayasu’s arteritis DOI Creative Commons

Shuning Guo,

Jiehan Li,

Shurui Pang

et al.

Arthritis Research & Therapy, Journal Year: 2025, Volume and Issue: 27(1)

Published: Jan. 20, 2025

Advances in treatment have swiftly alleviated systemic inflammation of Takayasu's arteritis (TAK), while subclinical vascular and the ensuing arterial remodeling continue to present unresolved challenges TAK. The phenotypic switching smooth muscle cells (VSMC) is regarded as first step pathology contributes remodeling. Exosomes facilitate transfer exchange proteins specific nucleic acids, thereby playing a significant role intercellular communication. Little known about modulatory serum exosomes VSMC Serum isolated from TAK patients were co-cultured with identify exosomes. transfected miR-199a-5p mimic inhibitor. CCK8 assays EdU performed measure proliferative ability. migration was evaluated by scratch transwell assays. flow cytometry employed apoptosis VSMC. Dual-luciferase reporter assay, RNA immunoprecipitation assay fluorescence situ hybridization utilized validate target gene miR-199a-5p. correlational analysis conducted among exosome miRNA, MMP2, TIMP2 clinical parameters patients. coculture mediated dedifferentiation Through gain- loss-of-function approaches, over-expression significantly increased expression marker genes inhibited proliferation migration, whilst opposite effect observed when endogenous knocked down. overexpression suppressed apoptosis. Further, MMP2 serves functional correlation analyses revealed an inverse between Vasculitis Damage Index level or which requires validation larger cohort. Our study indicated that miR-199a-5p/MMP2 pathway played inhibiting decreased secretion may potentially prompt intimal infiltration inflammatory within wall, offering novel therapeutic opportunity tackling both responses neointimal overgrowth associated damage. Moreover, derived possess potential future biomarkers for injury.

Language: Английский

Citations

1